文献速递瓣膜外科冠心病外科

经导管主动脉瓣置换失败后的外科取出

Surgical Explantation of Failed Transcatheter Aortic Valve Replacement.
PubMed 文献 · Ann Thorac Surg · 2023-06-22

基于多中心EXPLANT-TAVR注册研究199例患者的回顾性分析,比较单纯外科主动脉瓣置换(SAVR)与合并SAVR的TAVR取出术结局。合并SAVR组30天死亡率16.7% vs 9.9%、1年死亡率36.1% vs 22.1%,均未达统计学显著;3年累积生存率56.8% vs 81.1%(P=0.020),合并SAVR组显著更低。

要点

  • TAVR失败后外科取出时合并SAVR占47.2%(94/199),最常见为二尖瓣手术(45例)。
  • 合并SAVR组30天与1年死亡率数值更高但未达统计学显著(均P>.05)。
  • 合并SAVR组3年累积生存率显著更低(56.8% vs 81.1%,P=.020)。

核心结论

  • TAVR失败后外科取出时合并SAVR与死亡率增加相关。
  • 作者认为需要更长随访的进一步研究来检验在合并疾病发生前更早干预的获益。

研究设计与样本

  • 多中心EXPLANT-TAVR注册研究的回顾性分析,纳入2009年11月至2020年9月间接受TAVR取出的患者。
  • 纳入同期行合并手术的患者,排除与初始TAVR同一住院期间进行的取出及主动脉根部、升主动脉或主动脉弓的合并手术。
  • 比较单纯SAVR组与合并SAVR组的结局,中位随访6.6个月。

主要发现

  • 199例患者中94例(47.2%)行合并SAVR,主要为二尖瓣手术(n=45),其次为冠状动脉旁路移植术(n=23)。
  • 两组平均年龄相似(72.8 vs 73.4岁),合并SAVR组初始TAVR时STS预测死亡风险评分中位数更高(5.9% vs 3.7%,P=.001)。
  • 两组取出时间中位数无差异(12.9 vs 8.7个月,P=.78)。
  • 合并SAVR组平均体外循环时间(166 vs 114分钟,P=.001)和主动脉阻断时间(123 vs 81分钟,P=.001)更长。
  • 合并SAVR组30天死亡率(16.7% vs 9.9%)和1年死亡率(36.1% vs 22.1%)更高但均未达统计学显著(均P>.05);Kaplan-Meier分析3年累积生存率显著更低(56.8% vs 81.1%,P=.020)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Recent reports have demonstrated worse than expected outcomes of surgical explantation after transcatheter aortic valve replacement (TAVR). However in-depth analysis of the short- and mid-term risk of concomitant cardiac surgery at the time of TAVR explant is lacking. METHODS: Data from the multicenter EXPLANT-TAVR registry of patients undergoing TAVR-explant between November 2009 and September 2020 were retrospectively analyzed. Patients undergoing concomitant procedures were included, but explants performed during the same admission as the initial TAVR or concomitant procedures performed on the aortic root, ascending aorta, or arch were excluded. Outcomes were evaluated between the isolated surgical aortic valve replacement (SAVR) and concomitant SAVR groups. Median follow-up was 6.6 months. RESULTS: Among 199 patients, concomitant SAVR was performed in 94 patients (47.2%), primarily with mitral valve surgery (n = 45) followed by coronary artery bypass grafting (n = 23). Despite similar mean ages between groups (72.8 vs 73.4 years), concomitant SAVR had a higher median Society of Thoracic Surgeons Predicted Risk of Mortality score at the index TAVR (5.9% vs 3.7%, P = .001). There were no differences in median time-to-explant between groups (12.9 vs 8.7 months, P = .78). However concomitant SAVR had longer mean cardiopulmonary bypass (166 vs 114 minutes, P = .001) and cross-clamp times (123 vs 81 minutes, P = .001). Both 30-day (16.7% vs 9.9%) and 1-year mortality (36.1% vs 22.1%) were higher with concomitant SAVR but did not reach statistical significance (both P > .05). On Kaplan-Meier analysis, actuarial estimates of cumulative survival were significantly lower with concomitant SAVR at 3 years (56.8% vs 81.1%, P = .020). CONCLUSIONS: For surgical explantation after TAVR failure, concomitant SAVR is associated with increased mortality. Further studies with longer follow-up are warranted to examine the benefit from earlier intervention before concomitant disease develops.

来源:Ann Thorac Surg,查看原文。版权归原作者所有。

引用

  1. Zaid S, Hirji SA, Bapat VN, et al. Surgical Explantation of Failed Transcatheter Aortic Valve Replacement. Ann Thorac Surg. 2023. PMID: 37354965. doi:10.1016/j.athoracsur.2023.05.036

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。